Journal article

ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia

Gelareh Farshid, Michael Bilous, Adrienne Morey, Stephen Fox, Sunil Lakhani, Sherene Loi, Richard Bell, Andrew Spillane

PATHOLOGY | ELSEVIER SCIENCE BV | Published : 2019

Abstract

The latest update to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing in breast cancer guidelines was published in 2018. A multidisciplinary expert committee, convened under the auspices of the Royal College of Pathologists of Australasia (RCPA) Structured Pathology Reporting framework, evaluated the implications of these guidelines for clinical practice in Australia. Following feedback from professional bodies, including the RCPA and CanSAC, peer review was invited. The final document prepared by the authors, endorsed by the Expert Committee RCPA Structured Pathology Reporting of Breast Cancer and by CanSAC, is published herein.

Grants

Funding Acknowledgements

Gelareh Farshid, Michael Bilous, Adrienne Morey and Stephen Fox were previously members of the Roche HER2 Testing Advisory Board in Australia. Sunil Lakhani has received educational funding from Roche/Ventana and is on the ASCO ER/PgR panel. Richard Bell served on Advisory Boards for Roche.